Head-to-head evidence
Olodaterol vs salbutamol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
Olodaterol
Marketed by Boehringer Ingelheim
NCT00467740 · Phase 2 · completed
The study randomized 296 participants to placebo or one of four olodaterol doses, but the registry does not clearly report whether treatment assignment was blinded. Its primary outcome was a lung-function surrogate rather than a hard clinical outcome, and results were mixed across doses: only olodaterol 20 micrograms significantly improved trough FEV1 versus placebo at 4 weeks.
salbutamol
Developed by GlaxoSmithKline
NCT03528577 · Phase 3 · completed
The study randomized 128 participants in a quadruple-blind, four-period crossover design with active and placebo comparators. However, its primary endpoint was a pharmacodynamic surrogate rather than a hard clinical outcome. Results were not posted at the time of grading; the key result shown was recorded subsequently from the registry record.
Next expected readout: June 2027 · NCT06473779 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olodaterol's landscape · salbutamol's landscape